Nureca Ltd(NURECA)

NSE: NURECABSE: 543264

₹ 320.5-3.75%refreshed 23 Oct, 03:30 pm ISTMarket cap: ₹ 306 crWebsite: www.nureca.comUpdated: 24 Oct 2026

About

Nureca is a D2C-first consumer healthcare company in home healthcare and wellness devices, selling under the Dr Trust and Dr Physio brands. It reported FY26 revenue of Rs 146.96 Cr, and online sales made up more than 90% of revenue as of Q3 FY26. Its own plant at NTPL Mohali can make 8 lakh units a year, and in-house manufactured products accounted for 27% of revenue in Q1 FY27.^[1][2][3][4]

Business and segments

Nureca reports a single segment, India, with segment revenue of Rs 109.66 Cr in FY25.^[5]
Online sales made up more than 90% of revenue in Q3 FY26, against more than 93% in Q2 FY26.^[3][6]
In Q1 FY27, 27% of revenue came from products made in-house, up from 26% in FY26.^[4]

Products and brands

The company sells home healthcare and wellness devices under the Dr Trust and Dr Physio brands, and had 305+ active SKUs as of FY26.^[1]
The NTPL plant makes BP monitors, nebulizers, electric massagers, thermometers, heating pads, orthopedic cushions, breast pumps, vaporizers and stethoscopes.^[1]
20 new products were launched in Q4 FY26.^[7]
Launches in FY26 included pregnancy pillows, a pet thermometer, a red-light scalp massager, cervical pillows, braces and a coccyx cushion.^[6][3]
The Dr Trust 360 connected-health app had 2.4 million users in Q1 FY27, against 2 million+ in Q4 FY26, and now offers AI-powered health insights.^[4][7]

Manufacturing and approvals

The plant at NTPL Mohali has an annual capacity of 8 lakh units.^[1][4]
Average manufacturing lead time is 45 days, supported by exclusive ancillary suppliers and empanelled mould vendors (FY26).^[1]
As of FY26 the company held 15 CDSCO approvals, ISO 9001:2015 and ISO 13485:2016 certification, and USFDA 510K exempt approval for 16 products.^[1]
The company holds 102 patents as of FY26.^[1]
The company had 154 employees in FY26.^[1]

Key operating numbers

Gross merchandise value (GMV) was Rs 51.8 Cr in Q1 FY27, against INR 49.7 cr in Q4 FY26 (up 4% YoY). GMV for FY26 was INR 203 cr.^[4][7]
Gross margin was 38.8% in Q1 FY27. In FY26 it was 37%, down from 38%, because of extra discounting during sale events.^[4][1]
In Q1 FY27, offline revenue rose 57% YoY and 14% QoQ, and online sales rose 16% YoY and 5% QoQ.^[4]
The cumulative customer base was 17,508 thousand in H1 FY26, up from 16,460 thousand in FY25.^[6]
Advertising and promotion spend was INR 1.84 cr in Q4 FY26, INR 1.31 Cr in Q3 FY26 and INR 1.48 Cr in Q2 FY26.^[7][3][6]

Customers and distribution

As of FY26 the offline network had 285 distributors across 29 States & Union Territories, with a 52-member sales team. This compares with 192+ distributors in Q2 FY26.^[1][6]
Products are sold through Amazon, Blinkit, the company's own site drtrust.in, quick commerce, pharmacies, medical stores and modern retail (FY26).^[1]
Products have been launched and scaled on the Blinkit, Swiggy Instamart and Zepto quick-commerce platforms (FY25).^[5]
The company plans to use its US FDA registrations to expand exports into North America and the Middle East (FY25).^[5]

Expansion and capex

Subsidiary Nureca Technologies received industrial policy approval for a health and wellness equipment plant at Village Sundra, SAS Nagar, Punjab (FY25).^[5]
New land worth 66.65 million was bought in FY26, and building construction has progressed.^[1]
The company plans to expand Punjab manufacturing into medical devices, consumables and hygiene products to replace imports (Q1 FY27). The site was awaiting statutory approvals in Q3 FY26.^[4][3]
The company plans to widen offline coverage by adding super stockists and new distributors (Q1 FY27).^[4]

Market Cap

₹306 Cr

High / Low

₹375 / 200

Stock P/E

79.7

Price / Book

1.8

Book Value

₹189

EPS

₹2.2

No. of Shares

0.95 Cr

ROCE

3.3%

ROE

1.1%

OPM

4.0%

Debt / Equity

0.00

Sales

₹147 Cr

Net Profit

₹2 Cr

Promoter holding

70.7%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials